文献速递血管炎其他结缔组织病

骨髓增生异常综合征与慢性粒单核细胞白血病相关血管炎:法国多中心病例对照研究

Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
PubMed 文献 · Semin Arthritis Rheum · 2020-07-11

该回顾性病例对照研究纳入70例骨髓增生异常综合征(MDS)或慢性粒单核细胞白血病(CMML)相关血管炎患者,并与无自身免疫/炎症特征的MDS/CMML患者比较。血管炎诊断与MDS/CMML亚型及预后评分无关,对总生存无显著影响;传统DMARDs治疗者复发率更高,生物制剂或阿扎胞苷可考虑用于低危MDS/CMML血管炎。

要点

  • 血管炎可先于或后于MDS/CMML诊断,亚型分布及预后评分与无血管炎者无差异。
  • 传统DMARDs治疗者复发风险增高(OR 4.86),生物制剂和阿扎胞苷未显示复发差异。
  • 血管炎不影响总生存(p=0.5),但急性白血病进展率降低(log rank <0.05)。

核心结论

  • MDS/CMML相关血管炎的诊断与MDS/CMML亚型及严重程度无相关性,且对总生存无显著影响。
  • 传统DMARDs似乎疗效较差,生物制剂或阿扎胞苷可考虑用于甚至低危MDS/CMML血管炎。

研究设计与样本

  • 法国多中心回顾性描述性分析,纳入70例MDS/CMML相关血管炎患者,并与无免疫失调特征的MDS/CMML患者比较。
  • 中位年龄71.5岁[21-90],男女比2.3;中位随访33.2个月[1-162]。

主要发现

  • 血管炎在MDS/CMML之前诊断31例(44%),之后诊断20例。
  • 血管炎亚型包括巨细胞动脉炎24例(34%)、白塞样综合征11例(20%)、结节性多动脉炎6例(9%)。
  • 64/70例(91%)以糖皮质激素(GCs)为一线治疗,41例(59%)随访期间接受联合免疫抑制治疗。
  • 31例(44%)达到持续缓解,43例(61%)至少发生一次复发。
  • 与传统DMARDs相比,生物制剂(OR 0.59 [95%CI 0.11-3.20])和阿扎胞苷(OR 1.44 [95%CI 0.21-9.76])的复发率无差异。

关键数值与推荐

  • 传统DMARDs治疗者复发率更高(OR 4.86 [95%CI 1.38-17.10])。
  • MDS/CMML血管炎与无自身免疫/炎症特征者总生存无显著差异(p=0.5),但急性白血病进展率降低(log rank <0.05)。

临床怎么用

  • MDS/CMML患者合并血管炎时,治疗可考虑生物制剂或阿扎胞苷,尤其是传统DMARDs疗效不佳者。
  • 血管炎诊断不影响MDS/CMML预后分层,但需关注急性白血病进展风险可能降低。

局限性

  • 回顾性描述性分析,样本量70例,可能存在选择偏倚和信息偏倚。
  • 未报告血管炎治疗的具体剂量和疗程,以及不同亚型的独立分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Our objective was to evaluate characteristics, treatment and outcome of vasculitis associated with myelodysplastic syndrome (MDS) and chronic myelomonicytic leukemia (CMML) PATIENTS AND METHODS: Retrospective descriptive analysis of MDS/CMML-related vasculitis and comparison with MDS/CMML patients without dysimmune features. RESULTS: Seventy patients with vasculitis and MDS/CMML were included, with median age of 71.5 [21-90] years and male/female ratio of 2.3. Vasculitis was diagnosed prior to MDS/CMML in 31 patients (44%), and after in 20 patients. In comparison with MDS/CMML without autoimmune/inflammatory features, vasculitis with MDS/MPN showed no difference in MDS/CMML subtypes distribution nor International Prognostic Scoring System and CMML-specific prognostic (IPSS/CPSS) scores. Vasculitis subtypes included Giant cell arteritis in 24 patients (34%), Behçet's-like syndrome in 11 patients (20%) and polyarteritis nodosa in 6 patients (9%). Glucocorticoids (GCs) were used as first-line therapy for MDS/CMML vasculitis in 64/70 patients (91%) and 41 (59%) received combined immunosuppressive therapies during the follow-up. After a median follow-up of 33.2 months [1-162], 31 patients (44%) achieved sustained remission. At least one relapse occurred in 43 patients (61%). Relapse rates were higher in patients treated with conventional Disease Modifying Anti-Rheumatic Drug (DMARDs) (odds ratio 4.86 [95% CI 1.38 - 17.10]), but did not differ for biologics (odds ratio 0.59 [95% CI 0.11-3.20]) and azacytidine (odds ratio 1.44 [95% CI 0.21-9.76]) than under glucocorticoids. Overall survival in MDS/CMML vasculitis was not significantly different from MDS/CMML patients without autoimmune/inflammatory features (p = 0.5), but acute leukemia progression rates were decreased (log rank <0.05). CONCLUSION: This study shows no correlation of vasculitis diagnoses with subtypes and severity of MDS/CMML, and no significant impact of vasculitis on overall survival. Whereas conventional DMARDs seem to be less effective, biologics or azacytidine therapy could be considered for even low-risk MDS/CMML vasculitis.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Roupie AL, Guedon A, Terrier B, et al. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. Semin Arthritis Rheum. 2020. PMID: 32896704. doi:10.1016/j.semarthrit.2020.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。